<DOC>
	<DOCNO>NCT00695877</DOCNO>
	<brief_summary>Successful control HIV epidemic require safe effective vaccine develop . A successful vaccine need stimulate widespread immune response . The purpose study determine safety immune response adenovirus serotype HIV vaccine HIV uninfected adult .</brief_summary>
	<brief_title>Safety Immune Response Recombinant Adenovirus HIV-1 Vaccine Healthy Adults</brief_title>
	<detailed_description>Control HIV pandemic achieve development safe effective preventive HIV vaccine . A vaccine prevent HIV infection elicit strong immune response CD4 CD8 cell . Recombinant adenovirus serotype vector show elicit response . The purpose study determine safety immunogenicity recombinant adenovirus serotype 5 preventive HIV-1 vaccine . This study last 18 24 month . Participants randomly assign one four arm receive vaccine placebo administer via intramuscular injection . Participants Arms 1 , 2 , 3 receive 3 injection . Participants Arm 4 receive one injection . For participant , 10 study visit study ; participant Arm 4 , 7 visit . For Arms 1 , 2 , 3 , study visit occur baseline Days 0 , 14 , 28 , 42 , 56 , 168 , 182,196 , 365 . Participants Arms 1 , 2 , 3 receive injection Days 0 , 28 , 168 . For participant Arm 4 , study visit occur baseline Days 0 , 14 , 28 , 56 , 168 365 . Participants Arm 4 receive one injection , Day 0 . Participants ask record temperature side effect symptom log 3 day injection . Risk reduction/pregnancy prevention counsel physical exam occur visit . At visit , blood , urine , oral swab collection occur . Samples collect stored future test . HIV test pregnancy test occur select visit . At Years 2 , 3 , 4 , 5 , participant followed-up telephone , e-mail , study visit collect vital status , information development significant disability incapacity , hospitalization , congenital anomaly . At follow-up visit , blood collection optional .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Good general health Normal hematological , hepatic renal function Demonstrated understand study Willing receive HIV test result HIV1 2 uninfected Hepatitis B surface antigen negative Antihepatitis C virus ( antiHCV ) negative antibody negative HCV PCR antiHCV positive Adequate contraception . For information criterion find protocol . HIV vaccine placebos prior HIV vaccine trial Immunosuppressive medication within 168 day prior first injection . Participants take corticosteroid nasal spray topical corticosteroid exclude . Blood product within 120 day prior first injection Immunoglobulin within 60 day prior first injection Investigational agent within 30 day prior first injection Live attenuate vaccine within 30 day prior first injection Any vaccine live attenuate vaccine within 14 day prior first injection Any clinically significant medical condition , opinion investigator , may interfere study Any medical , psychiatric , occupational , social condition responsibility , opinion investigator , would interfere study Serious adverse reaction vaccine . Participants nonanaphylactic adverse reaction pertussis vaccine child exclude . Known autoimmune disease Known immunodeficiency Asthma mild , wellcontrolled asthma Diabetes mellitus type 1 2 Thyroidectomy thyroid disease the12 month prior study entry Angioedema 3 year prior study entry Hypertension . More information criterion find protocol . Body mass index ( BMI ) 40 high OR BMI 35 great , cardiovascular risk factor . More information criterion find protocol . Bleeding disorder Malignancy , unless surgically remove , opinion investigator , likely recur study period Seizure disorder occurrence seizure 3 year prior study entry . Participants required medication seizure prior 3 year exclude . Absence spleen Individuals highrisk acquire HIV infection Presence preexist neutralize antibody Adenovirus 5 48 Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>